Moderna Outlines Strategy to Address SARS-CoV-2 Variants; Ships Variant Booster to NIH for Testing
The NIAID will evaluate the vaccine candidate, mRNA-1273.351, against the SARS-CoV-2 variant, B.1.351.
Vaccines
Nationwide Study Shows BNT162b2 mRNA Vaccine Is Effective
In mass vaccination setting, vaccine is effective for symptomatic COVID-19, hospitalization, severe disease, death
Tick-Borne Encephalitis Vaccine Gets Priority Review
TicoVac is an inactivated whole virus vaccine developed using a master ‘seed’ virus that is similar to the tick-borne encephalitis virus found in nature.
COVID-19 Vaccines Adapted to Fight Variants Will Not Require Long Clinical Trials: FDA
Most makers of approved COVID-19 vaccines have said they plan to adapt their vaccines to tackle variants
SARS-CoV-2, COVID-19 Rates Decreased After One Vaccine Dose
Study among health care workers shows reductions in SARS-CoV-2 infection rates one to 14, 15 to 28 days after first dose of the BNT162b2 COVID-19 vaccine
CDC Report Shows No Evidence of Unexpected Adverse Events With COVID-19 Vaccines
Findings from the first month show no unexpected adverse events, with 6,994 adverse events and >90 percent classified as nonserious
Updates to the 2021 Adult Immunization Schedule
The ACIP emphasizes the importance of routine vaccinations during the pandemic to prevent diseases.
Pfizer-BioNTech: COVID-19 Vaccine Trial in Pregnant Women Begins; New Storage Data Submitted to FDA
The randomized, placebo-controlled, observer-blind study is evaluating the safety, tolerability, and immunogenicity of BNT162b2 in approximately 4000 healthy pregnant women aged 18 years and older who are 24 to 34 weeks’ gestation.
COVID-19 Vaccines for US Children Still Months Away
Pfizer and Moderna conducting trials of their vaccines in children 12 and older and hope to have findings by the summer
Many Health Care Workers Report Vaccine Hesitancy
However, data are from survey conducted prior to U.S. emergency use authorization of any vaccines
